Who
Pharis Mohideen
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, DBV Technologies; Chief Medical Officer, Tempest Therapeutics.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $49K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 7 Dec 2018
- Last trade
- 29 Jul 2026
- Last filed
- 31 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jul 2026filed 31 Jul 2026 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $1,253464 at $2.70 | filing |
| 29 Jul 2026filed 31 Jul 2026 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $1,253464 at $2.70 | filing |
| 29 Jan 2026filed 2 Feb 2026 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $2,595534 at $4.86 | filing |
| 29 Jan 2026filed 2 Feb 2026 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $2,595534 at $4.86 | filing |
| 21 Nov 2025filed 25 Nov 2025 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —253,000 at $0.00 | filing |
| 21 Nov 2025filed 25 Nov 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $4,4981,624 at $2.77 | filing |
| 21 Nov 2025filed 25 Nov 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 20 Nov 2025filed 25 Nov 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $19K6,496 at $2.88 | filing |
| 29 Jul 2025filed 31 Jul 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $1,030464 at $2.22 | filing |
| 22 May 2025filed 27 May 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $730397 at $1.84 | filing |
| 30 Jan 2025filed 31 Jan 2025 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $510600 at $0.85 | filing |
| 25 Nov 2024filed 27 Nov 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $322565 at $0.57 | filing |
| 22 Nov 2024filed 27 Nov 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $181342 at $0.53 | filing |
| 21 Nov 2024filed 25 Nov 2024 | DBVT DBV Technologiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,000 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 21 Nov 2024filed 25 Nov 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $1,2692,350 at $0.54 | filing |
| 29 Jul 2024filed 31 Jul 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $1,7491,785 at $0.98 | filing |
| 24 May 2024filed 29 May 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $898660 at $1.36 | filing |
| 22 May 2024filed 29 May 2024 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $527382 at $1.38 | filing |
| 22 Nov 2023filed 19 Dec 2023 | DBVT DBV TechnologiesBiotechnology | SEC FORM 4 Sold | $3,9062,245 at $1.74 | filing |
News
DBV Technologies (NASDAQ:DBVT) Sets New 52-Week Low – What's Next?DBVT · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Pharis Mohideen; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.